Objective: To interrogate a poly-T variant (rs10524523, 9523) in TOMM40, a gene adjacent to the APOE gene on chromosome 19, in older persons with APOE e3/3 homozygosity for association with cognitive decline, the clinical hallmark of Alzheimer disease (AD).
of the relationship between the 9523 variant and cognitive decline is limited. The only 2 studies of which we are aware had relatively few numbers of longitudinal assessments; one had biannual assessments with a mean of z6 years, 14 and the other had up to 4 assessments in 5-year intervals. 15 Here, we investigate the effect of the TOMM409523 variant on cognitive decline by leveraging genetic and longitudinal cognitive data from .1,000 community-based older persons who were APOE e3/3 homozygous and were followed annually for up to 21 years. We summarize the distribution of 9523 length variation and examine its association with decline in global cognition and 5 relatively dissociable cognitive domains.
METHODS Study participants. Data came from 2 ongoing cohort studies of aging and dementia, the Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP). 16, 17 The 2 studies are conducted by the same team of investigators with similar data collection procedures and share a common core of testing batteries. This design allows combined analyses. Study participants were free of known dementia at enrollment, underwent annual clinical and neuropsychological evaluations, and agreed to annual blood draws and brain donation at the time of death.
Considering APOE/TOMM40 evolutionary history, 18 we restricted our sample to participants of European ancestry. At the time of analyses, genotyping data were available on 2,072 (96.6%) of the 2,144 white participants who completed the baseline evaluation. We excluded 116 participants who were diagnosed with AD dementia at baseline and another 70 who had only one cognitive evaluation. Of the remaining 1,886 individuals, 417 (22.1%) had APOE e4 (e3/4 or e4/4), 261 (13.9%) had e2 (e2/2 or e2/3), and 38 (2.0%) had e2/4. Our analyses focused on the 1,170 participants (62.0%) who were APOE e3/3 homozygous. The mean age at baseline was 78.5 years (SD 5 7.4 years, range 54.3-97.8 years); the majority were female (n 5 825, 70.5%); and the mean years of education was 16.2 (SD 5 3.5 years, range 5-30 years). These participants were followed up annually for up to 21 years, with a mean of 8.2 years (SD 5 5.0).
Standard protocol approvals, registrations, and patient consent. The studies were approved by the Institutional Review Board of Rush University Medical Center. Written informed consent was acquired from each participant, and all participants signed an Anatomic Gift Act for organ donation.
Cognitive assessments. For each participant, comprehensive cognitive assessments were administered at baseline and each annual follow-up visit. 19 The testing battery contains a total of 17 cognitive performance tests that assess 5 cognitive domains, including episodic memory, semantic memory, working memory, perceptual speed, and visuospatial ability. Composite measures were used to examine the longitudinal cognitive decline, as previously described. 20 More details on the cognitive tests are provided in the e-Methods at Neurology.org. The Mini-Mental State Examination was used only for descriptive purpose.
Results from the cognitive testing were reviewed by a neuropsychologist for signs of cognitive impairment. Clinical judgment of AD dementia follows standard criteria and requires a history of cognitive decline and evidence of impairment in memory and at least one other cognitive domain. 21 APOE and TOMM409523 genotyping. DNA was extracted from peripheral blood or frozen postmortem brain tissue. Genotyping was performed at Polymorphic DNA Technologies (Alameda, CA) by investigators blinded to all clinical and pathologic data. The APOE genotypes were determined by sequencing rs429358 (codon 112) and rs7412 (codon 158) at exon 4 of the APOE gene. The TOMM409523 genotypes were determined by rs10524523 (chr19:44,899,792-44,899,826, human genome reference assembly GRCh38/hg38), a homopolymer-length polymorphism (poly-T), at intron 6 of the TOMM40 gene. 7, 18 On the basis of the length of the poly-T repeat, a short allele (9523-S) was defined by poly-T repeat #19, a long allele (9523-L) by 20 # poly-T repeat # 29, and a very long allele (9523-VL) by poly-T repeat $30.
Statistical analysis. Analysis of variance, Kruskal-Wallis, and x 2 tests examined the bivariate relationship of the TOMM409523 genotypes with baseline age, education, sex, length of follow-up, and baseline cognition. Linear mixed models tested the hypothesis that in APOE e3/3 carriers the rate of linear decline in cognition differs by 9523 genotype. In the primary model, annual summary scores for global cognition are the longitudinal continuous outcome. The main predictors include a term for time in years since the baseline that estimates the mean rate of change in cognition (slope). The interaction terms of the 9523 genotypes and time examine the associations of the 9523 variant with the slope. We repeated the model for each of the 5 cognitive domains separately. The analyses were done with SAS/STAT software, version 9.3 for Linux (SAS Institute Inc, Cary, NC).
For older persons who died, the longitudinal cognitive trajectory features a precipitous drop a few years before death, commonly known as terminal decline. 22 We reported previously that APOE e4 was associated with both preterminal and terminal decline. 23 Therefore, we explored the influence of the 9523 variant on terminal decline by using random change point models, a common modeling approach for nonlinear change. 24, 25 The model specification has been described previously. 26 The model estimates different rates of decline before and after a change point that signals the acceleration of cognitive decline. The model examines the association of risk factors with the onset of accelerated decline (i.e., terminal decline) and the rate of decline before and after the onset. These analyses were done with OpenBUGS. 27 All the models were controlled for age, sex, and education. Unless otherwise specified, statistical significance was determined a priori at an a level of 0.05.
RESULTS Distribution of TOMM409523 among APOE e3/3 carriers. The APOE e3 allele was linked predominantly to either the 9523-S or 9523-VL allele (figure e-1). Of the 1,170 e3/3 carriers in this study, 310 (26.5%) were 9523-S/S homozygous, 568 (48.5%) were 9523-S/VL heterozygous, and 281 (24.0%) were 9523-VL/VL homozygous. Fewer than 1% of the participants who had other 9523 genotypes (including 5 S/L and 6 L/VL cases) were excluded from the subsequent association analyses.
The baseline descriptives of study participants with the 3 major TOMM409523 genotypes are summarized in table 1. We did not observe difference in demographics or length of follow-up by 9523 genotype. In addition, there was no difference in baseline cognition.
TOMM409523 and decline in global cognition. We first examined the association of TOMM409523 with decline in global cognition. In the model adjusted for baseline age, sex, and education, we observed that the mean annual rate of change in global cognition was 20.051 (standard error [SE] 5 0.004, p , 0.001). We then augmented the model by including terms for the 9523 genotypes. Participants with 9523-S/S homozygosity had faster cognitive decline than those with 9523-S/VL (estimate 5 20.021, SE 5 0.007, p 5 0.003) or 9523-VL/VL (estimate 5 20.017, SE 5 0.008, p 5 0.030). Post hoc comparison did not reveal a significant difference between 9523-S/VL and VL/VL carriers in cognitive decline (p 5 0.628), suggesting that the 9523-S/S genotype was associated with faster decline in a recessive manner. For model parsimony, we refitted the model by collapsing the S/VL and VL/ VL into one group. As shown in figure 1 , participants with 9523-S/S genotype had z40% faster decline in global cognition than the rest of e3/3 carriers (p 5 0.002). Depression might affect the association with cognitive decline; thus, we repeated the last model by controlling for depressive symptoms. Participants with more depressive symptoms had faster decline, but the association of 9523 genotype with cognitive decline was unchanged.
TOMM409523 and decline in 5 cognitive domains. We repeated the linear mixed model and examined the effect of 9523-S/S genotype on decline in individual cognitive domains. As shown in table 2, among e3/3 carriers, the presence of 9523-S/S genotype was associated with faster decline in episodic memory (p , 0.001) and semantic memory (p 5 0.003). In Next, we focused on the subsample of the deceased participants and examined the associations of 9523-S/S with terminal decline in cognition. The average age at death was 89.2 years (SD 5 6.4 years). Table 3 summarizes the results from the random change point models. Consistent with our previous report for the overall cohorts, 28 in this sample, the terminal decline in global cognition occurred a mean of z3.4 years before death, and the mean decline in the terminal phase was 7 times faster than the preterminal phase. We found that the rate of terminal decline in global cognition was faster in participants with the 9523-S/S genotype compared to those without (figure 2). Similar results were observed in episodic memory and semantic memory. We did not find a significant difference in the onset of terminal decline by 9523-S/S status. The findings were inconclusive with respect to the effect of 9523-S/S on preterminal decline; the 9523-S/S genotype was associated with faster preterminal decline in semantic memory, but the associations with decline in global cognition and episodic memory were not significant. DISCUSSION The genetic role of TOMM40 in AD remains controversial because of its linkage disequilibrium with APOE. 29 Studies targeting APOE 3/3 homozygosity are able to disentangle the effect of the TOMM40 variant independent of potential confounding due to e4 or e2. Recent phylogenetic analyses reveal that in whites the APOE e3 allele is linked to the variable length at TOMM409523 such that AD susceptibility differs depending on whether e3 is linked to a 9523-S or -VL allele. 6 Findings to date, however, are mixed. The 9523-VL allele has been shown to be related to earlier disease onset, poorer memory performance, or smaller gray matter volume, suggesting that 9523-VL increases the risk of AD. 7, 8, 30, 31 Null or even conflicting findings have also been reported. [9] [10] [11] 32, 33 Using annual cognitive data from .1,000 community-based older white Americans who were e3/3 homozygous, we examined the effect of the 9523 variant on late-life cognitive decline, We found that the e3/3 in linkage to 9523-S/S is associated with faster decline in cognition compared with the linkage to either S/VL or VL/VL. The effect is driven primarily by episodic and semantic memory. This result supports that, although APOE and TOMM409523 are in linkage disequilibrium, the APOE-TOMM409523 haplotypes are more informative than the APOE genotypes alone in relation to cognitive decline. The direction of effect suggests that 9523-S rather than -VL is the potential risk allele. Our result is consistent with that from an earlier large-scale casecontrol study showing that, among individuals with e3/3 genotype, the frequency of 9523-VL is lower in Table 2 TOMM409523-S/S genotype is associated with faster cognitive decline patients with AD than in controls. 9 We observed that the 9523-S allele influences cognitive decline in a recessive manner such that, compared with S/S, e3/3 in linkage to both S/VL and VL/VL shows slower decline, and we did not find a difference between S/VL and VL/VL. In addition, although prior literature suggests that the effect of TOMM409523 is most evident at younger ages, 14 in a subsample of deceased participants, we observed that the 9523-S/S genotype is associated with faster terminal decline. We previously reported a similar finding for APOE such that the e4 allele not only contributes to the preterminal decline in cognition that occurs many years before death but also expedites the progression of dementia and influences cognition during the last few years of life.
23 Table 3 TOMM409523-S/S genotype is associated with faster terminal decline Global cognition estimates (95% CI) Episodic memory estimates (95% CI) Semantic memory estimates (95% CI)
Global cognition proximate to death The underlying neurobiology of the effect of TOMM409523 on cognitive decline is unclear, but the structural variants show effects in an array of neurologic areas. Findings from brain pathology of individuals with APOE e3/3 show that the 9523 long allele (poly-T repeat $20) may increase the burden of AD pathology. 34 Prior evidence also suggests that the 9523 variant may have a broader influence in other common neurodegenerative diseases, including Parkinson disease. 35 The TOMM40 variant is implicated in affecting the level of neurofilament light proteins in CSF, a marker primarily for subcortical axonal injury and white matter disease. 36 Older adults with the 9523-S allele also have lower white matter integrity. 37 Beyond these studies specifically on TOMM40, the question of the extent to which results previously thought to relate purely to APOE e4 may use a 9523-dependent mechanism is unanswered. For instance, although a few studies have found 9523 brain structure, far more extensive work in APOE e4 has found that major connectivity tracts are affected at birth 38 and that it ultimately disrupts the balance of specialized processing and information integration in normal brain networks. 39 Moving beyond these disease associations toward some understanding of the role of 9523 in AD is difficult because the molecular pathways behind them are unclear.
To better define disease mechanisms in the future, the molecular effects of the APOE-TOMM409523 haplotypes can be evaluated with a traditional focus on the sequence and chromatin state of that specific locus or from a global multi-omic perspective. For instance, methylation patterns at the locus coupling the 2 genes lead to an allele-specific effect on the expression levels of both genes. 40 Examining effects beyond this locus may also be necessary, given the pleiotropy of APOE, the need to compare APOE and TOMM40 effects, and the broad role for molecular interactions in determining cellular state and AD susceptibility. 39 Common examples of such broader approaches are coexpression or comethylation. These approaches can identify genome-wide sets of covarying genes, which can then be associated with disease state or genes with key disease variants. Indeed, the structure of these networks themselves may be altered in association with disease state or the presence of a given haplotype. Furthermore, directed causal networks leverage genetic variants to infer directed interactions and to help identify a sequence of signaling downstream of genetic variants. Novel omic assays can help to estimate these molecular effects. For instance, because 9523 is intronic, comparative chromatin conformation could be used to identify transcriptional regulatory changes due to higher-order chromatin state changes. Because APOE variants affect protein structure, the binding partners of APOE alleles may differ, and such knowledge would reduce the number of critical partners for disease effects. Overall, applying these omic approaches will assist in identifying the union, intersection, and interacting effects of TOMM40 and APOE in a manner that points to disease mechanisms.
The strength of the study is noted. A majority of previous reports on TOMM40 effects focus on age at onset or rely on case-control studies, and we elected to use the endophenotype of longitudinal cognitive decline. AD has been reconceptualized as a continuum from normality to mild cognitive impairment to AD dementia. By capitalizing on continuous repeated measures of cognitive performance, our approach avoids the potential confounding due to preclinical or subclinical contamination in the reference group, and the quantitative nature of the phenotype improves the statistical power to detect small effects. The study also has limitations. The ROS and MAP participants on average are older and have more education than the general population. Our findings need to be replicated in other studies, including studies that use alternative cognitive metrics.
The current study is restricted to the e3/3 carriers in white Americans. The APOE-TOMM409523 linkage patterns are different in blacks as a result of admixture. It is important to distinguish the APOE-TOMM409523 haplotypes between older white and black populations. Finally, future studies are needed to examine whether the relationship between TOMM409523 and cognition is driven by AD pathology. All the ROS and MAP participants are organ donors. However, only a subset of the study sample had died and undergone brain autopsy. As more postmortem samples are being collected, the 2 studies offer a unique opportunity to investigate this important question with the needed fidelity.
